Pharma BD Deal Intelligence
On June 29, 2026, Ipsen entered a definitive merger agreement to acquire US hemato-oncology biotech Kartos Therapeutics for $450 million upfront at closing plus up to $1.3 billion in milestones (regulatory-approval and sales-based), for total potential consideration of up to ~$1.75 billion. The deal adds navtemadlin (KRT-232), an investigational oral MDM2 inhibitor designed to restore p53 tumor-suppressor function, being evaluated as add-on to ruxolitinib in myelofibrosis patients with suboptimal response (Phase 3 POIESIS; top-line data expected 2027). The transaction is expected to close by end of Q3 2026 and to be accretive to Ipsen core operating income from 2029.